Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Lennox-Gastaut syndrome (LGS), also known as Lennox syndrome, is a difficult-to-treat form of childhood-onset epilepsy that most often appears between the second and sixth year of life, and is characterized by frequent seizures and different seizure types; it is often accompanied by mental retardation and behavior problems.
- 1 Characteristics
- 2 Incidence and prevalence
- 3 Mortality and morbidity
- 4 Causes
- 5 Diagnosis
- 6 Treatment
- 7 History
- 8 End notes
- 9 Further reading
- 10 See also
- 11 External links
Characteristics[edit | edit source]
As a general rule, the age of seizure onset in LGS patients is between the ages of two and six; however, this does not exclude the possibility that seizures can begin before age two, or after age eight. The syndrome shows clear parallels to West syndrome, enough to suggest a connection.
Daily multiple seizures are typical in LGS. Also typical is the broad range of seizures that can occur, larger than that of any other epileptic syndrome. The most frequently occurring seizure types are: tonic, which are often nocturnal (90%); the second most frequent are myoclonic seizures, which often occur when the patient is over-tired.
Atonic, atypical absence, complex partial, focalized and tonic-clonic seizures are also common. Additionally, about half of patients will suffer from status epilepticus, usually the nonconvulsive type, which is characterized by dizziness, apathy, and unresponsiveness. The seizures can cause sudden falling (or spasms in tonic, atonic and myoclonic episodes) and/or loss of balance, which is why patients often wear a helmet to prevent head injury.
In addition to daily multiple seizures of various types, children with LGS frequently have arrested/slowed psychomotor development and behavior disorders.
Incidence and prevalence[edit | edit source]
Approximately 5% of children with epilepsy have LGS, and is more common in males than females. Whereas some children seem perfectly normal prior to the development of seizures, others already had some form of epilepsy, such as West syndrome, which is seen in 20% of patients before (symptomatic) LGS. West syndrome is characterized by Blitz Nick Salaam seizures, and typically evolves into LGS in the second year of life.
Finland[edit | edit source]
According to a 1997 community-based retrospective study in the Helsinki metropolitan area and the province of Uusimaa, the annual incidence of both Lennox-Gastaut was 2 in 100,000 (0.002%) from 1975-1985.
United States[edit | edit source]
0.026% of all children in the Atlanta, Georgia metropolitan area were estimated to have LGS in 1997, which was defined as, "onset of multiple seizure types before age 11 years, with at least one seizure type resulting in falls, and an EEG demonstrating slow spike-wave complexes (<2.5 Hz)." The study concluded that LGS accounts for 4% of childhood epilepsies.
Mortality and morbidity[edit | edit source]
The mortality rate ranges from 3% to 7%.
Causes[edit | edit source]
There is no uniform cause: in 20% of the concerned, the LGS develops from the West syndrome. The medical history frequently includes infantile spasms or focalized and generalized seizures.
The most common type of LGS (70-78%). This does not mean that LGS patients in other categories have no symptoms whatsoever; rather, it means that there is an identifiable underlying pathology responsible. This includes encephalopathy (brain damage) or another disease and/or developmental disorder. Frequent causes include tuberous sclerosis, hereditary metabolic diseases, inflammatory brain disease such as encephalitis, meningitis, and toxoplasmosis; hypoxia-ischemia injury and other birth injuries; and lesions of the frontal lobe. These patients tend to have a worse prognosis than the idiopathic ones.
In up to one-third of cases no cause can be found. These cases are referred as cryptogenic and/or idiopathic Lennox-Gastaut syndrome. Patients are considered to have idiopathic LGS if they were developing normally prior to the seizures, and cryptogenic if a cause is suspected by unknown. Not all investigators mention the second category.
Diagnosis[edit | edit source]
Generally speaking, LGS can often only be defined as a syndrome and/or distinguished from other syndromes because there are various overlaps with other syndromes. Currently, the fact that there is no uniform cause complicates things.
- CT scans, usually in the case of suspected injury resulting from an atonic and/or tonic seizure.
Treatment[edit | edit source]
LGS seizures are often treatment resistant, but this does not mean that treatment is futile. Options include anticonvulsants, anesthetics, steroids such as prednisone, immunoglobulins, and various other pharmacological agents that have been reported to work in individual patients.
Pharmacological[edit | edit source]
Approved[edit | edit source]
First-line drugs[edit | edit source]
- valproates (valproic acid, sodium valproate and valproate semisodium)
- benzodiazepines, specifically clonazepam, nitrazepam, and clobazam
Nitrazepam and Clobazam are not approved in the USA.
Second-line drugs[edit | edit source]
In 1999, Dr. Sachdeo and colleagues at the University of Medicine and Dentistry of New Jersey and the Robert Wood Johnson Medical School in New Brunswick reported that 33% of the patients in the topiramate group experienced a minimum 50% reduction in seizures (specifically drop attacks and tonic-clonics), compared with 8% in the placebo group. It was also found to be effective as an adjunctive therapy in a review published by Drs. Edith Alva Moncayo and Antonio Ruiz Ruiz in March of 2003.
Dr. Motte and colleagues at the American Memorial Hospital at Reims, France reported in 1997 that lamotrigine was effective in the treatment of LGS, with the most common side effect in the treatment group relative to placebo being colds or viral illnesses. Two years later, it was approved by Health Canada for adjunctive therapy in Lennox Gastaut in adults and children. The United States Food and Drug Administration approved it for that in August of 1998.
Felbamate was found to be superior to placebo in controlling treatment resistant partial seizures and atonic seizures. However, it has been known to cause aplastic anemia and liver toxicity.
Unapproved, off-label, and investigational drugs[edit | edit source]
Vigabatrin was found by Feucht et al to be an effective add-on in patients whose seizures were not satisfactorily controlled by valproate. Out of 20 children, only 1 experienced a serious side effect (dyskinesia).
Zonisamide showed promise in an overview of controlled and uncontrolled trials conducted in Japan. However, in a physician survey conducted December of 2004, only 28% of Lennox-Gastaut and West syndrome patients improved on zonisamide.
Surgical[edit | edit source]
Other[edit | edit source]
Ketogenic diet[edit | edit source]
- Main article: [[Ketogenic diet]]
Intravenous immunoglobulin therapy[edit | edit source]
Intravenous immunoglobulin therapy has been used in Lennox-Gastaut syndrome as early as 1986, when van Rijckevorsel-Harmant and colleagues used it in seven patients with ostensibly idiopathic LGS and saw EEG improvement and decreased seizure frequency in six of them.
Hippotherapy[edit | edit source]
Hippotherapy is a form of physical, occupational, or speech therapy that utilizes the movement of a horse. It can be an effective treatment for some of the symptoms of Lennox-Gastaut syndrome, including developmental delays and communication problems. Hippotherapy has proven effective in increasing the walking speed and other gross motor functions in children with Lennox-Gastaut syndrome.
History[edit | edit source]
End notes[edit | edit source]
- Childhood seizures - epilepsy and convulsions in children. URL accessed on August 16, 2005.
- Heiskala H. (1997). Community-based study of Lennox-Gastaut syndrome. Epilepsia 38 (5): 526-31. PMID 9184597.
- Trevathan E, Murphy CC, Yeargin-Allsopp M. (1997). [Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia 38 (12): 1283-8. PMID 9578523.
- Glauser, Tracy A. and Morita, Diego A. (2002). Introduction. Lennox-Gastaut Syndrome. eMedicine.com, Inc.. URL accessed on 8 July, 2005.
- Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G (1999). [A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 10 (52): 1882-7. PMID 10371538.
- Alva-Moncayo E, Ruiz-Ruiz A (2003). [The value of topiramate used with conventional schemes as an adjunctive therapy in the treatment of Lennox-Gastaut syndrome]. Revista de Neurologia 36 (5): 453-7. PMID 12640599.
- Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P (1997). Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. New England Journal of Medicine 337 (25): 1807-12. PMID 9400037.
- Epilepsy Ontario (1999). Lamotrigine Approved in Canada for Lennox-Gastaut Syndrome. 'Sharing' News. URL accessed on 13 November, 2005.
- Glaxo Wellcome Inc (1998). Final Printed Labeling -- Part 1. Lamictal Tablets & Chewable Dispersible Tablets (Lamotrigine) Drug Approval Page. United States Food and Drug Administration Center for Drug Evaluation and Research. URL accessed on 13 November, 2005.
- Ritter, Frank J., Ilo E. Leppik, Fritz E. Dreifuss, Ihor Rak, Nancy Santilli, Roberta Homzie, W. Edwin Dodson, Tracy A. Glauser, J. Chris Sackellares, Larry Olson, Elizabeth A. Garafolo, W. Donald Shields, Jacqueline French, Michael Sperling, Lynn D. Kramer, Marc Kamin, Alberto Rosenberg, Robert Shumaker, James L. Perhach, and Robert Dix (1993). Efficacy of Felbamate in Childhood Epileptic Encephalopathy (Lennox-Gastaut Syndrome). New England Journal of Medicine 328 (1): 29-33. PMID 8347179.
- Devinsky, Orrin, R. Edward Faught, B. Joseph Wilder, Andres M. Kanner, Marc Kamin, L. D. Kramer and A. Rosenberg (1995). Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Research 20 (3): 241-6. PMID 7796796.
- O'Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S (1996). Felbamate-associated fatal acute hepatic necrosis. Neurology 46 (5): 1457-1459. PMID 8628501.
- Feucht M, Brantner-Inthaler S (1994). Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia 35 (5): 993-8. PMID 7925171.
- Yagi K (2004). Overview of Japanese experience-controlled and uncontrolled trials. Seizure 13 (Supplement 1): S11-5; discussion S16. PMID 15511680.
- Yamauchi, Toshio, Aikawa Hiroshi (December 2004). Efficacy of zonisamide: our experience. Seizure 13 (Suppl 1): S41-8 discussion S49. DOI:10.1016/j.seizure.2004.04.021.
- van_Rijckevorsel-Harmant, K., M. Delire and M. Rucquoy-Ponsar (1986). Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins. European Archives of Psychiatry and Neurological Sciences 236 (2): 119-22. PMID 3792407.
Further reading[edit | edit source]
- Möglichkeit zur Bestellung einer Informationsmappe zum Lennox-Gastaut-Syndrom
- Krämer, Günter & Sälke-Kellermann, R. A. (Hrsg.): Das Lennox-Gastaut-Syndrom (1998) ISBN 3-89412-341-9
- Schneble, Hansjörg: Epilepsie bei Kindern - Wie Ihre Familie damit leben lernt (1999) ISBN 3-89373-528-3
- Puckhaber, Haiko: Epilepsie im Kindesalter [Epilepsy in Infancy] (2000) ISBN 3-88074-240-5
- Altrup, Ulrisch & Elger, Christian: Epilepsie - Informationen in Texten und Bildern (2000) ISBN 3-933185-49-1
- Krämer, Günter: Diagnose Epilepsie (2003) ISBN 3-8304-3077-9
See also[edit | edit source]
[edit | edit source]
- eMedicine - Lennox-Gastaut Syndrome : Article by Tracy A. Glauser, MD
- Informationsseite für Eltern von Kindern mit Epilepsie (Information site for parents of children with epilepsy) (German)
- Adressliste der Epilepsiezentren in Deutschland (Address list of Epilepsy Centers in Germany) (German)
- fr:Syndrome de Lennox-Gastaut
- fi:Lennox-Gastautin oireyhtymä
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|